MERRIMACK PHARMACEUTICALS IN (MACK)

US5903282094 - Common Stock

15.13  0 (0%)

After market: 15.16 +0.03 (+0.2%)

News Image
4 days ago - InvestorPlace

MACK Stock Earnings: Merrimack Pharmaceuticals Reported Results for Q1 2024

Merrimack Pharmaceuticals just reported results for the first quarter of 2024.

News Image
2 months ago - Merrimack Pharmaceuticals, Inc.

Merrimack Receives $225 Million Milestone Payment from Ipsen

News Image
2 months ago - InvestorPlace

MACK Stock Earnings: Merrimack Pharmaceuticals Reported Results for Q4 2023

Merrimack Pharmaceuticals just reported results for the fourth quarter of 2023.

News Image
2 months ago - Merrimack Pharmaceuticals, Inc.

Merrimack Reports Full Year 2023 Financial Results

News Image
5 months ago - Market News Video

Friday 12/29 Insider Buying Report: MACK, EWTX

News Image
6 months ago - Market News Video

Friday 11/17 Insider Buying Report: MACK, DAR

News Image
7 months ago - Merrimack Pharmaceuticals, Inc.

Merrimack Reports Third Quarter 2023 Financial Results

News Image
8 months ago - USA News Group

Pancreatic Cancer Battle Boosted by $200M VC Firm

/PRNewswire/ -- USA News Group - A new cancer-focused venture capital firm is making headlines, having debuted with $200 million in funding from prominent...

News Image
8 months ago - FinancialNewsMedia

Pancreatic Cancer Battle Boosted by $200M VC Firm

EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:MACK),(NASDAQ:INCY),(NASDAQ:MRTX),(NASDAQ:BNTX) EQNX::TICKER_END

News Image
9 months ago - Market News Video

Thursday 8/10 Insider Buying Report: CVBF, MACK

News Image
10 months ago - Merrimack Pharmaceuticals, Inc.

Merrimack Reports Second Quarter 2023 Financial Results

News Image
a year ago - Merrimack Pharmaceuticals, Inc.

Merrimack Reports First Quarter 2023 Financial Results

News Image
a year ago - InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

We're beginning the day with a look at the biggest pre-market stock movers traders need to know about for Wednesday morning!

News Image
a year ago - Merrimack Pharmaceuticals, Inc.

Merrimack Reports Full Year 2022 Financial Results

News Image
2 years ago - FinancialNewsMedia

Biotech Sector Witnessing Growing Revenue Potential in Ongoing Battle Against Pancreatic Cancer

FN Media Group Presents USA News Group News Commentary   Vancouver, BC –November 15, 2022 – USA News Group  –  Roughly five years after selling its flagship cancer asset Onivyde from to French biotech giant Ipsen S.A. for approximately $1 billion, Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) is still reaping the drug’s benefit despite being a shuttered […]

News Image
2 years ago - FinancialNewsMedia

Biotechs with Evolving Therapies Have Potential to Revolutionize Treatments for Pancreatic Cancer

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:MACK),(NASDAQ:NRBO),(NYSE:MRK),(NASDAQ:RNAZ), EQNX::TICKER_END

News Image
2 years ago - FinancialNewsMedia.com

Biotechs with Evolving Therapies Have Potential to Revolutionize Treatments for Pancreatic Cancer

/PRNewswire/ -- FinancialNewsMedia.com News Commentary - The pancreatic cancer treatment market is fiercely competitive. To maintain the escalating market...

News Image
2 years ago - InvestorPlace

Upstart (UPST) Stock Sinks on Gloomy Forecast

Upstart (UPST) stock is sliding lower on Wednesday following a poor performance in the third quarter of 2022 and a weak outlook.